Released Aug 14, 2018, after the close
10-Q filed Aug 14, 2018, 45 days after period end · 0001390478-18-000022
Q2 2018 · 10-Q
Revenue—
Net Income-$6.06M-$6.06M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$1.26-$1.26 N/M vs Q2 2017N/M vs Q1 2018
Operating Cash Flowderived-$6,299,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2013 |
|---|---|---|---|---|
| Revenue | — | — | — | $3.38M |
| Net Income | -$6.06M | -$5.91M | $5.39M | $5.39M |
| EPS Diluted | -$1.26 | -$0.22 | $0.58 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR